
SEL-201
CAS No. 2095704-43-9
SEL-201( SLV-2436 | SEL201-88 )
Catalog No. M13299 CAS No. 2095704-43-9
SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 97 | In Stock |
![]() ![]() |
5MG | 160 | In Stock |
![]() ![]() |
10MG | 260 | In Stock |
![]() ![]() |
25MG | 496 | In Stock |
![]() ![]() |
50MG | 714 | In Stock |
![]() ![]() |
100MG | 981 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSEL-201
-
NoteResearch use only, not for human use.
-
Brief DescriptionSEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor.
-
DescriptionSEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor with IC5010.8/5.4 nM, respectively; displays acceptable kinome selectivity in the broad KINOMEscan (450 distinct kinases); potently suppresses MNK1/2 activity in a panel of KIT-mutant melanoma cell lines, reduces clonogenicity, migration, and lung metastasis of KIT-mutant melanoma cells both in vitro and in vivo.
-
In VitroTo confirm the kinome selectivity of SLV-2436 (SEL201), the broad KINOMEscan competitive binding assay is performed at 1 μM, which includes 450 distinct kinases. The observed binding profile for SLV-2436 is significantly concentrated in the CAMK family of kinases that comprises MNK1 and MNK2. SLV-2436-treated KIT-mutant melanoma cells have lower oncogenicity and reduced metastatic ability.
-
In VivoTo investigate the pharmacodynamic properties of SLV-2436 (SEL201), 5 consecutive oral doses of 10, 25, and 50 mg/kg are administered to mice every 12 hours (twice-daily schedule). At the 10 mg/kg twice-daily dosage, 4 hours after the fifth administration, a low plasma concentration of 125 ng/mL SLV-2436 is determined. However, dosing at 25 and 50 mg/kg twice daily, equivalent to 50 and 100 mg/kg/d of SLV-2436, yields substantially increased dose-dependent plasma exposure, reaching an average level of 1,299 ng/mL and 2,075 ng/mL, respectively. At the 24-hour time point, SLV-2436 is still detectable in the plasma, with dose-dependent concentrations of 9, 73, and 124 ng/mL in the 10, 25, and 50 mg/kg twice-daily treatment groups. Oral (p.o.) administration of SLV-2436 at the dosage of 50 mg/kg twice daily, that is, 100 mg/kg/d, for 37 days is well tolerated in mice.
-
SynonymsSLV-2436 | SEL201-88
-
PathwayMAPK/ERK Signaling
-
TargetMNK
-
RecptorMNK1|MNK2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number2095704-43-9
-
Formula Weight350.806
-
Molecular FormulaC19H15ClN4O
-
Purity>98% (HPLC)
-
Solubility< 1 mg/ml refers to the product slightly soluble or insoluble
-
SMILESC1=CC(=CC(=C1)Cl)CN2C=C(C=CC2=O)C3=CC4=C(C=C3)C(=NN4)N
-
Chemical Name5-(3-amino-1H-indazol-6-yl)-1-[(3-chlorophenyl)methyl]-1,2-dihydropyridin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhan Y, et al. J Clin Invest. 2017 Nov 1;127(11):4179-4192.
molnova catalog



related products
-
Cercosporamide
A broad-spectrum natural antifungal compound that acts as a selective and highly potent fungal Pkc1 kinase inhibitor.
-
EB1
EB1 is a potent and selective MNK kinase inhibitor with inhibitory effects on MNK1 and MNK2 with IC50 values of 0.69 μM and 9.4 μM, respectively.
-
MNK inhibitor 9
MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).